Coya Therapeutics (COYA) Competitors $6.41 +0.24 (+3.89%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$6.39 -0.02 (-0.30%) As of 02/21/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends COYA vs. AKBA, KALV, SAGE, PRTC, ARCT, ORGO, SIGA, CDXC, KROS, and ABVXShould you be buying Coya Therapeutics stock or one of its competitors? The main competitors of Coya Therapeutics include Akebia Therapeutics (AKBA), KalVista Pharmaceuticals (KALV), Sage Therapeutics (SAGE), PureTech Health (PRTC), Arcturus Therapeutics (ARCT), Organogenesis (ORGO), SIGA Technologies (SIGA), ChromaDex (CDXC), Keros Therapeutics (KROS), and ABIVAX Société Anonyme (ABVX). These companies are all part of the "pharmaceutical products" industry. Coya Therapeutics vs. Akebia Therapeutics KalVista Pharmaceuticals Sage Therapeutics PureTech Health Arcturus Therapeutics Organogenesis SIGA Technologies ChromaDex Keros Therapeutics ABIVAX Société Anonyme Coya Therapeutics (NASDAQ:COYA) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Does the media refer more to COYA or AKBA? In the previous week, Akebia Therapeutics had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 2 mentions for Akebia Therapeutics and 0 mentions for Coya Therapeutics. Akebia Therapeutics' average media sentiment score of 0.43 beat Coya Therapeutics' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Coya Therapeutics Neutral Akebia Therapeutics Neutral Do analysts rate COYA or AKBA? Coya Therapeutics presently has a consensus price target of $16.25, indicating a potential upside of 153.51%. Akebia Therapeutics has a consensus price target of $7.50, indicating a potential upside of 316.67%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Coya Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, COYA or AKBA? Coya Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoya Therapeutics$6M17.85-$7.99M-$0.65-9.86Akebia Therapeutics$194.62M2.02-$51.92M-$0.23-7.83 Do institutionals and insiders believe in COYA or AKBA? 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Comparatively, 4.1% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is COYA or AKBA more profitable? Coya Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -27.07%. Akebia Therapeutics' return on equity of 0.00% beat Coya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Coya TherapeuticsN/A -31.63% -27.76% Akebia Therapeutics -27.07%N/A -20.57% Which has more risk & volatility, COYA or AKBA? Coya Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Does the MarketBeat Community prefer COYA or AKBA? Akebia Therapeutics received 397 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 95.00% of users gave Coya Therapeutics an outperform vote while only 63.41% of users gave Akebia Therapeutics an outperform vote. CompanyUnderperformOutperformCoya TherapeuticsOutperform Votes1995.00% Underperform Votes15.00%Akebia TherapeuticsOutperform Votes41663.41% Underperform Votes24036.59% SummaryAkebia Therapeutics beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks. Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COYA vs. The Competition Export to ExcelMetricCoya TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$103.08M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.5616.5114.19Price / Sales17.85304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book2.606.717.644.63Net Income-$7.99M$138.11M$3.18B$245.69M7 Day Performance-5.74%-2.54%-1.95%-2.68%1 Month Performance13.25%-2.00%-0.23%-2.16%1 Year Performance-25.64%-5.04%16.69%12.90% Coya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COYACoya Therapeutics1.4378 of 5 stars$6.41+3.9%$16.25+153.5%-26.3%$103.08M$6M0.006High Trading VolumeAKBAAkebia Therapeutics3.9788 of 5 stars$2.10-1.9%$7.50+257.1%+26.8%$458.18M$194.62M-9.13430Analyst DowngradeKALVKalVista Pharmaceuticals4.6917 of 5 stars$9.19-0.1%$23.80+159.0%-23.1%$454.15MN/A-2.52100Short Interest ↓News CoverageSAGESage Therapeutics4.6184 of 5 stars$7.26+0.1%$10.53+45.0%-67.1%$444.12M$106.40M-1.30690PRTCPureTech Health2.1488 of 5 stars$18.35-3.9%$45.00+145.2%-20.7%$439.30M$3.33M0.00100ARCTArcturus Therapeutics2.6141 of 5 stars$16.11-0.5%$65.00+303.5%-49.6%$436.42M$169.93M-7.26180Gap UpORGOOrganogenesis3.9644 of 5 stars$3.57+3.2%$5.00+40.1%-6.4%$435.01M$455.04M-59.50950News CoverageGap UpSIGASIGA Technologies1.3863 of 5 stars$6.07+3.8%N/A+13.9%$433.40M$139.92M5.0640Options VolumeNews CoverageCDXCChromaDex4.4076 of 5 stars$5.60+1.4%$8.00+42.9%+256.6%$427.73M$83.57M560.56120News CoverageKROSKeros Therapeutics3.437 of 5 stars$10.49-3.4%$52.56+401.0%-81.6%$424.95M$150,000.00-2.01100ABVXABIVAX Société Anonyme2.0154 of 5 stars$6.63+5.2%$38.67+483.2%-33.4%$420.14MN/A0.0061News Coverage Related Companies and Tools Related Companies Akebia Therapeutics Competitors KalVista Pharmaceuticals Competitors Sage Therapeutics Competitors PureTech Health Competitors Arcturus Therapeutics Competitors Organogenesis Competitors SIGA Technologies Competitors ChromaDex Competitors Keros Therapeutics Competitors ABIVAX Société Anonyme Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COYA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COYA Stock Alerts